Risk Of Developing Liver Cancer After HCV Treatment

Monday, March 19, 2012

2012-New guidelines on the management of hepatocellular carcinoma (HCC).

EASL-EORTC publish joint Clinical Practice Guidelines on the management of Hepatocellular Carcinoma

PDF Download -
View the clinical practice guidelines on the management of hepatocellular carcinoma (HCC).

The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma (HCC). The EASL-EORTC guidelines define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.

HCC is the most common form of liver cancer, representing more than 90% of primary liver cancers and an increasing global health burden. It is estimated that, by 2020, the number of cases will reach 78,000 in Europe (up from 65,000 in 2008) and 27,000 in the US (up from 21,000 in 2008). Affecting 2.4 times more men than women, approximately 90% of HCCs are associated with a known underlying risk factor - the most frequent including chronic viral hepatitis (types B and C), alcohol intake and aflatoxin exposure.

Lead author Professor Josep M Llovet said: “Despite the availability of effective surveillance and treatment strategies for HCC, the proportion of patients currently receiving these interventions is suboptimal. When considered in light of HCC’s growing European and global incidence, it is critical that measures are implemented to increase access to surveillance, early diagnosis and effective treatment.”

EASL-Website

No comments:

Post a Comment